Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.
2.

Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS).

Saponara M, Urbini M, Astolfi A, Indio V, Ercolani G, Del Gaudio M, Santini D, Pirini MG, Fiorentino M, Nannini M, Lolli C, Mandrioli A, Gatto L, Brandi G, Biasco G, Pinna AD, Pantaleo MA.

Oncotarget. 2015 Dec 8;6(39):42243-57. doi: 10.18632/oncotarget.6278.

4.

Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.

Alturkmani HJ, Pessetto ZY, Godwin AK.

Expert Opin Investig Drugs. 2015;24(8):1045-58. doi: 10.1517/13543784.2015.1046594. Epub 2015 Jun 22. Review.

5.

Expression profile of microRNAs in gastrointestinal stromal tumors revealed by high throughput quantitative RT-PCR microarray.

Tong HX, Zhou YH, Hou YY, Zhang Y, Huang Y, Xie B, Wang JY, Jiang Q, He JY, Shao YB, Han WM, Tan RY, Zhu J, Lu WQ.

World J Gastroenterol. 2015 May 21;21(19):5843-55. doi: 10.3748/wjg.v21.i19.5843.

6.

Gastrointestinal stromal tumor - an evolving concept.

Tornillo L.

Front Med (Lausanne). 2014 Nov 11;1:43. doi: 10.3389/fmed.2014.00043. eCollection 2014. Review.

7.

Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs).

Campanella NC, Celestino R, Pestana A, Scapulatempo-Neto C, de Oliveira AT, Brito MJ, Gouveia A, Lopes JM, Guimarães DP, Soares P, Reis RM.

Eur J Hum Genet. 2015 Jun;23(6):877-9. doi: 10.1038/ejhg.2014.195. Epub 2014 Sep 24.

8.

GEIS 2013 guidelines for gastrointestinal sarcomas (GIST).

Poveda A, del Muro XG, López-Guerrero JA, Martínez V, Romero I, Valverde C, Cubedo R, Martín-Broto J.

Cancer Chemother Pharmacol. 2014 Nov;74(5):883-98. doi: 10.1007/s00280-014-2547-0. Epub 2014 Sep 6. Review.

9.

The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.

Boikos SA, Stratakis CA.

Endocrine. 2014 Nov;47(2):401-8. doi: 10.1007/s12020-014-0346-3. Epub 2014 Jul 16. Review.

10.

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.

Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR.

Oncotarget. 2014 Apr 15;5(7):1926-41.

11.

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.

Serrano C, Wang Y, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA.

J Clin Oncol. 2015 Aug 1;33(22):e93-6. doi: 10.1200/JCO.2013.48.7488. Epub 2014 Mar 31. No abstract available.

12.

MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.

Gits CM, van Kuijk PF, Jonkers MB, Boersma AW, van Ijcken WF, Wozniak A, Sciot R, Rutkowski P, Schöffski P, Taguchi T, Mathijssen RH, Verweij J, Sleijfer S, Debiec-Rychter M, Wiemer EA.

Br J Cancer. 2013 Sep 17;109(6):1625-35. doi: 10.1038/bjc.2013.483. Epub 2013 Aug 22.

13.

Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors.

Belinsky MG, Rink L, von Mehren M.

Front Oncol. 2013 May 17;3:117. doi: 10.3389/fonc.2013.00117. eCollection 2013.

14.

Gastrointestinal stromal tumors.

Miettinen M, Lasota J.

Gastroenterol Clin North Am. 2013 Jun;42(2):399-415. doi: 10.1016/j.gtc.2013.01.001. Epub 2013 Mar 13. Review.

15.

Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors.

Belinsky MG, Rink L, Flieder DB, Jahromi MS, Schiffman JD, Godwin AK, Mehren Mv.

Genes Chromosomes Cancer. 2013 Feb;52(2):214-24. doi: 10.1002/gcc.22023. Epub 2012 Oct 29.

16.

Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors.

Celestino R, Lima J, Faustino A, Vinagre J, Máximo V, Gouveia A, Soares P, Lopes JM.

Eur J Hum Genet. 2013 May;21(5):503-10. doi: 10.1038/ejhg.2012.205. Epub 2012 Sep 5.

17.

Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.

Kee D, Zalcberg JR.

Ther Adv Med Oncol. 2012 Sep;4(5):255-70. doi: 10.1177/1758834012450935.

18.

Pathology of gastrointestinal stromal tumors.

Foo WC, Liegl-Atzwanger B, Lazar AJ.

Clin Med Insights Pathol. 2012;5:23-33. doi: 10.4137/CPath.S9689. Epub 2012 Jul 17.

19.

Recent advances and novel agents for gastrointestinal stromal tumor (GIST).

Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath SM, Liu D.

J Hematol Oncol. 2012 May 8;5:21. doi: 10.1186/1756-8722-5-21. Review.

20.

qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL.

Fassunke J, Blum MC, Schildhaus HU, Zapatka M, Brors B, Künstlinger H, Büttner R, Wardelmann E, Merkelbach-Bruse S.

BMC Mol Biol. 2010 Dec 20;11:100. doi: 10.1186/1471-2199-11-100.

Items per page

Supplemental Content

Write to the Help Desk